Litigation Details for Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2013)
Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2013)
| Docket | 1:13-cv-01874 | Date Filed | 2013-11-08 |
| Court | District Court, D. Delaware | Date Terminated | 2019-10-17 |
| Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
| Jury Demand | None | Referred To | |
| Parties | PHARMASCIENCE INC. | ||
| Patents | 6,713,446; 6,958,319 | ||
| Attorneys | Steven J. Fineman | ||
| Firms | Smith, Katzenstein, & Jenkins LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc.
Details for Millennium Pharmaceuticals Inc. v. Zydus Pharmaceuticals (USA) Inc. (D. Del. 2013)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2013-11-08 | External link to document | |||
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
Millennium Pharmaceuticals v. Zydus Pharmaceuticals: Litigation Summary, Patent Scope, and Generic Entry Risk
Millennium Pharmaceuticals sued Zydus Pharmaceuticals in the District of Delaware over Zydus’ abbreviated new drug application for generic bortezomib for injection, the generic version of Velcade. The case, No. 1:13-cv-01874, centered on U.S. Patent No. 8,338,047, which claimed a stable, lyophilized bortezomib formulation containing mannitol. The litigation ended without a publicly reported merits judgment against Zydus. Its commercial significance increased after the Federal Circuit upheld the validity of the same patent in related litigation against Teva and other generic applicants.
What was Millennium Pharmaceuticals v. Zydus Pharmaceuticals about?
Millennium’s complaint challenged Zydus’ ANDA under the Hatch-Waxman Act. Millennium alleged that Zydus’ proposed generic product would infringe claims of U.S. Patent No. 8,338,047, titled “Bortezomib formulations” (Millennium Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:13-cv-01874, D. Del.).
The accused product was a generic injectable formulation of bortezomib, the active ingredient in Velcade. Velcade is used principally in multiple myeloma and mantle cell lymphoma.
Case profile
| Item | Detail |
|---|---|
| Court | U.S. District Court for the District of Delaware |
| Case number | 1:13-cv-01874 |
| Plaintiff | Millennium Pharmaceuticals, Inc. |
| Defendant | Zydus Pharmaceuticals (USA) Inc. |
| Reference product | Velcade |
| Active ingredient | Bortezomib |
| Regulatory pathway | ANDA |
| Primary patent | U.S. Patent No. 8,338,047 |
| Patent subject | Lyophilized bortezomib formulation |
| Filing period | 2013 |
| Procedural outcome | Terminated before a publicly reported merits judgment against Zydus |
What patent protected Velcade in the Zydus litigation?
The central patent was U.S. Patent No. 8,338,047. It covered a pharmaceutical formulation of bortezomib in which mannitol forms a boronic ester with bortezomib during lyophilization. The formulation was developed to improve stability and permit reconstitution for injection.
The patent was important because the original bortezomib formulation had stability and manufacturing limitations. The patented composition became the formulation associated with commercial Velcade.
U.S. Patent No. 8,338,047
| Patent attribute | Detail |
|---|---|
| Patent number | 8,338,047 |
| Title | Bortezomib formulations |
| Inventive subject | Lyophilized bortezomib and mannitol formulation |
| Assignee | Millennium Pharmaceuticals, Inc. |
| Priority period | 2007 |
| Issue date | December 25, 2012 |
| Listed expiration | August 7, 2027 |
| Product relevance | Velcade for Injection |
| Litigation relevance | Core patent in Millennium’s generic challenges |
The patent did not merely claim bortezomib as a molecule. Its value came from the formulation and manufacturing characteristics that allowed bortezomib to be supplied as a stable injectable product.
When did the Velcade formulation patent expire?
The listed expiration date for U.S. Patent No. 8,338,047 was August 7, 2027, subject to any applicable patent-term adjustment or regulatory exclusivity treatment reflected in the relevant FDA and USPTO records.
The patent’s expiration date was materially later than the expiration of Millennium’s earlier bortezomib compound patent. That distinction created a second exclusivity barrier for generic injectable products.
Velcade patent timeline
| Date | Event |
|---|---|
| 2003 | FDA approved Velcade |
| 2007 | Priority filings supporting the later formulation patent |
| December 25, 2012 | U.S. Patent No. 8,338,047 issued |
| 2013 | Millennium filed the Zydus infringement action |
| 2017 | Federal Circuit upheld the validity of the ’047 patent in related litigation |
| August 7, 2027 | Listed expiration of the ’047 patent |
What did Zydus challenge under Paragraph IV?
Zydus’ ANDA certification placed the ’047 patent in dispute under the Hatch-Waxman framework. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.
Millennium’s lawsuit triggered the statutory 30-month stay of FDA approval, subject to the specific timing of the notice letter, complaint, and any intervening court orders. The litigation therefore had two commercial effects:
- It delayed potential FDA approval of Zydus’ ANDA.
- It required Zydus to address the formulation patent before launching a product that could compete directly with Velcade.
The publicly available litigation record does not establish that Zydus obtained a final judgment invalidating the ’047 patent or a judicial declaration of non-infringement.
How strong was Millennium’s patent position?
The ’047 patent became stronger after the Federal Circuit reversed a district court decision that had found the patent obvious in related litigation.
In Millennium Pharmaceuticals, Inc. v. Sandoz Inc., the Federal Circuit held that the asserted claims were not obvious on the record before it. The court rejected the argument that a skilled artisan would have had a reasonable expectation of success in arriving at the claimed lyophilized formulation from the prior art (Millennium Pharmaceuticals, Inc. v. Sandoz Inc., 862 F.3d 1356, 2017).
The Federal Circuit’s reasoning focused on the unpredictability of the formulation work. The prior art disclosed bortezomib, mannitol, lyophilization, and related pharmaceutical techniques, but the court found that the combination did not make the claimed formulation obvious merely because the individual elements were known.
Patent-strength assessment
| Factor | Assessment |
|---|---|
| Claim type | Formulation and process-related claims |
| Anticipation risk | Lower than for a broad chemical claim because the claims required a specific formulation architecture |
| Obviousness risk | Reduced after the Federal Circuit’s 2017 decision |
| Design-around risk | Present, depending on formulation composition and manufacturing process |
| Enforcement value | High for generic injectable bortezomib products using the claimed formulation |
| Remaining weakness | The patent did not necessarily block every possible bortezomib formulation |
The Federal Circuit decision did not automatically decide the Zydus case. It did, however, remove a major invalidity precedent that generic defendants could have used against Millennium.
What was the litigation outcome?
The Zydus action was terminated without a publicly reported trial judgment establishing that Zydus infringed or that the ’047 patent was invalid. The case record indicates resolution before a final merits determination.
The public record does not disclose commercially material settlement terms such as:
- An authorized-generic arrangement;
- A specific Zydus launch date;
- A royalty structure;
- A license to manufacture or distribute bortezomib;
- A covenant not to sue for particular formulations; or
- A launch date tied to patent expiration.
The absence of a merits judgment means the case should not be characterized as a judicial victory by either party. The related Federal Circuit ruling, however, materially improved Millennium’s negotiating position in parallel bortezomib cases.
Did the Zydus case involve a settlement agreement?
The case ended without a public merits opinion resolving the ’047 patent’s validity or infringement as to Zydus. Hatch-Waxman cases that terminate in this posture commonly reflect a settlement, voluntary dismissal, or another negotiated resolution.
A settlement may have limited the availability of commercially relevant details. The public record does not provide a complete set of settlement terms sufficient to calculate Zydus’ agreed launch date or the economic consideration exchanged.
That limitation matters for market forecasting. A terminated case does not necessarily mean that Zydus was free to launch immediately. Its ability to market the product could still have depended on FDA approval, patent restrictions, settlement conditions, manufacturing readiness, and the scope of the ANDA product.
What was the Orange Book status of the Velcade formulation patent?
U.S. Patent No. 8,338,047 was listed in the FDA Orange Book for Velcade for Injection. Orange Book listing gave Millennium the ability to invoke Hatch-Waxman litigation against ANDA applicants that certified against the patent.
The listing was particularly important because the patent covered the commercial formulation rather than only the active pharmaceutical ingredient. A generic applicant could face infringement risk even if the molecule itself was no longer protected, provided the proposed product used the patented formulation.
Orange Book and regulatory significance
The relevant legal distinction was:
- The active ingredient patent addressed bortezomib as a compound.
- The ’047 patent addressed the injectable formulation.
- The ANDA applicant had to address each listed patent through the applicable certification.
- A Paragraph IV notice created a litigation pathway and could delay approval through the statutory stay.
FDA approval and patent clearance were separate issues. FDA approval did not eliminate infringement exposure, and settlement of the patent case did not guarantee immediate regulatory approval.
What generic entry risks existed for Zydus?
Zydus faced three principal entry risks.
Formulation infringement
The main risk was that the proposed product used the patented bortezomib-mannitol formulation or a formulation that met the asserted claim limitations. A product could infringe even if it used a different manufacturing process, depending on the claim language and the final composition.
Invalidity risk
The Federal Circuit’s 2017 decision reduced the probability that a generic defendant could invalidate the ’047 patent through an obviousness theory based on routine formulation work. The ruling did not eliminate all validity defenses, including written-description, enablement, anticipation, and enforceability arguments.
Commercial launch risk
Zydus also faced the possibility that a settlement would impose a delayed entry date. Delayed entry could be commercially rational if the patent estate remained difficult to defeat and the market had limited room for multiple injectable bortezomib suppliers.
How did the Zydus case compare with related Velcade litigation?
The Zydus case was part of a broader series of Velcade patent disputes involving generic manufacturers, including Teva, Sandoz, Actavis, and other ANDA applicants.
The central common issue was the validity and scope of the ’047 formulation patent. In the related Millennium v. Sandoz appeal, the Federal Circuit reversed the district court’s obviousness ruling and upheld the asserted claims. That appellate decision affected the bargaining position of generic defendants across the wider litigation group.
| Issue | Zydus case | Related Millennium v. Sandoz litigation |
|---|---|---|
| Product | Generic bortezomib injection | Generic bortezomib injection |
| Core patent | U.S. Patent No. 8,338,047 | U.S. Patent No. 8,338,047 |
| Final merits decision | No public merits judgment against Zydus | Federal Circuit decision in 2017 |
| Validity result | Not finally adjudicated publicly in the Zydus docket | Claims upheld against obviousness challenge |
| Commercial effect | Delayed or conditioned generic entry | Strengthened Millennium’s position in related cases |
Did the case create biosimilar risk?
No. Bortezomib is a small-molecule drug, not a biologic. The relevant competitors were ANDA-based generic manufacturers, not biosimilar applicants under the Biologics Price Competition and Innovation Act.
The competitive risks were therefore driven by:
- Paragraph IV certifications;
- Patent litigation;
- Formulation design-arounds;
- FDA ANDA approval;
- Manufacturing capacity; and
- Settlement-controlled launch timing.
What manufacturing and intellectual-property barriers remained?
The ’047 patent created a manufacturing barrier because the claimed product depended on more than the presence of bortezomib. The formulation required a particular interaction between bortezomib and mannitol during lyophilization.
A generic manufacturer seeking to avoid infringement could attempt to develop:
- A different bulking agent;
- A different stabilizer system;
- A different pH or reconstitution profile;
- A different lyophilization cycle; or
- A different chemical form of bortezomib.
Each design-around could create new regulatory and development burdens. The alternative formulation would need to demonstrate pharmaceutical equivalence or otherwise satisfy FDA requirements while preserving stability, sterility, reconstitution performance, and clinical comparability.
What was the commercial exposure for Millennium?
Velcade was a major oncology product for Millennium and its parent company, Takeda Pharmaceutical Company. Generic entry threatened revenue from injectable bortezomib, particularly in multiple myeloma, where treatment duration and combination regimens supported recurring demand.
The commercial exposure was concentrated in the injectable formulation covered by the ’047 patent. The patent’s later expiration date provided Millennium with a potentially meaningful period of protection beyond the earlier compound patent.
Precise case-specific revenue allocation to the Zydus dispute is not established by the litigation docket. The economic impact depended on whether Zydus launched, the launch timing agreed in any settlement, the number of competing generics, and the rate of price erosion after entry.
Key Takeaways
- Millennium sued Zydus in Delaware over an ANDA for generic bortezomib for injection.
- The principal patent was U.S. Patent No. 8,338,047, covering a lyophilized bortezomib-mannitol formulation.
- The patent had a listed expiration date of August 7, 2027.
- The case ended without a publicly reported merits judgment against Zydus.
- The Federal Circuit later upheld the ’047 patent against an obviousness challenge in related litigation.
- The case involved generic entry risk, not biosimilar risk.
- Publicly available records do not establish Zydus’ negotiated launch date or complete settlement economics.
- Millennium’s formulation patent was commercially significant because it protected the injectable product used in Velcade rather than only the bortezomib molecule.
FAQs About Millennium v. Zydus
What drug was at issue in Millennium v. Zydus?
The case involved bortezomib for injection, the generic equivalent of Velcade for Injection.
Which patent did Millennium assert against Zydus?
Millennium asserted U.S. Patent No. 8,338,047, directed to a lyophilized bortezomib formulation containing mannitol.
Did Zydus invalidate Millennium’s Velcade patent?
No public merits judgment in the Zydus case invalidated U.S. Patent No. 8,338,047.
Was Zydus allowed to launch generic bortezomib before 2027?
The public litigation record does not establish an unrestricted Zydus launch before the patent’s listed expiration date. Any launch rights would have depended on FDA approval, patent status, and the terms of the case resolution.
Was Millennium v. Zydus a biosimilar lawsuit?
No. It was a Hatch-Waxman ANDA case involving a small-molecule generic, not a biosimilar application.
References
-
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Millennium Pharmaceuticals, Inc. v. Zydus Pharmaceuticals (USA) Inc., No. 1:13-cv-01874, U.S. District Court for the District of Delaware.
-
Millennium Pharmaceuticals, Inc. v. Sandoz Inc., 862 F.3d 1356 (Fed. Cir. 2017).
-
U.S. Patent No. 8,338,047. (2012). Bortezomib formulations. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2003). Velcade approval and prescribing information. U.S. Department of Health and Human Services.
More… ↓
